Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

17.49USD
17 Aug 2018
Change (% chg)

$-1.34 (-7.12%)
Prev Close
$18.83
Open
$18.73
Day's High
$18.73
Day's Low
$17.05
Volume
133,378
Avg. Vol
171,650
52-wk High
$31.69
52-wk Low
$12.51

Chart for

About

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The... (more)

Overall

Beta: --
Market Cap(Mil.): $982.56
Shares Outstanding(Mil.): 56.18
Dividend: --
Yield (%): --

Financials

  APLS.OQ Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -1.65 -- --
ROI: -65.34 12.92 12.63
ROE: -120.58 14.94 14.82

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

Feb 22 2018

Earnings vs. Estimates